Figure S1  Body surface identification of sentinel lymph node biopsy before operation. (A) ○ represent the location of the tumor; ● represent the location of SLN, and ~ represents the pathway of lymphatic drainage; (B) ○ represent the location of the tumor; ● represent the location of SLN, and ~ represents the pathway of lymphatic drainage. SLN, sentinel lymph node.

Figure S2  Flow of participants. CEUS, contrast-enhanced ultrasonography; SLNB, sentinel lymph node biopsy; ALND, axillary lymph node dissection.
<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No. of cases</th>
<th>SLN, n (%)</th>
<th>No. of cases</th>
<th>SLN, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤35</td>
<td>5</td>
<td>(100.0)</td>
<td>0</td>
<td>(0)</td>
</tr>
<tr>
<td>35–50</td>
<td>29</td>
<td>22 (75.9)</td>
<td>7 (24.1)</td>
<td></td>
</tr>
<tr>
<td>&gt;50</td>
<td>39</td>
<td>21 (53.9)</td>
<td>18 (46.1)</td>
<td></td>
</tr>
<tr>
<td><strong>BMI</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;25</td>
<td>45</td>
<td>37 (82.2)</td>
<td>8 (17.8)</td>
<td></td>
</tr>
<tr>
<td>≥25</td>
<td>28</td>
<td>21 (75.0)</td>
<td>7 (25.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Menopausal status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-menopausal</td>
<td>45</td>
<td>39 (86.7)</td>
<td>6 (13.3)</td>
<td></td>
</tr>
<tr>
<td>Post-menopausal</td>
<td>28</td>
<td>19 (67.9)</td>
<td>9 (32.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Family history</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>57</td>
<td>45 (78.9)</td>
<td>12 (21.1)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>16</td>
<td>13 (81.3)</td>
<td>3 (18.7)</td>
<td></td>
</tr>
<tr>
<td><strong>Tumor location</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Central</td>
<td>4</td>
<td>4 (100)</td>
<td>0</td>
<td>(0)</td>
</tr>
<tr>
<td>Outer upper</td>
<td>43</td>
<td>34 (79.1)</td>
<td>9 (20.9)</td>
<td></td>
</tr>
<tr>
<td>Outer lower</td>
<td>11</td>
<td>7 (63.6)</td>
<td>4 (36.4)</td>
<td></td>
</tr>
<tr>
<td>Inner upper</td>
<td>3</td>
<td>3 (100)</td>
<td>0</td>
<td>(0)</td>
</tr>
<tr>
<td>Inner lower</td>
<td>12</td>
<td>10 (83.3)</td>
<td>2 (16.7)</td>
<td></td>
</tr>
<tr>
<td><strong>Excision biopsy</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>59</td>
<td>46 (78.0)</td>
<td>13 (22.0)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>14</td>
<td>12 (85.7)</td>
<td>2 (14.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Tumor size</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T1mi</td>
<td>5</td>
<td>5 (100)</td>
<td>0</td>
<td>(0)</td>
</tr>
<tr>
<td>T1</td>
<td>31</td>
<td>20 (64.5)</td>
<td>11 (35.5)</td>
<td></td>
</tr>
<tr>
<td>T2</td>
<td>37</td>
<td>30 (81.1)</td>
<td>7 (18.9)</td>
<td></td>
</tr>
<tr>
<td><strong>Histologic grade</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G1</td>
<td>9</td>
<td>8 (88.9)</td>
<td>1 (11.1)</td>
<td></td>
</tr>
<tr>
<td>G2</td>
<td>53</td>
<td>41 (77.4)</td>
<td>12 (22.6)</td>
<td></td>
</tr>
<tr>
<td>G3</td>
<td>11</td>
<td>9 (81.8)</td>
<td>2 (18.2)</td>
<td></td>
</tr>
<tr>
<td><strong>Lympho-vascular invasion</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>55</td>
<td>51 (94.4)</td>
<td>4 (7.3)</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>18</td>
<td>7 (38.9)</td>
<td>11 (61.1)</td>
<td></td>
</tr>
<tr>
<td><strong>Pathology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IDC</td>
<td>46</td>
<td>37 (80.4)</td>
<td>9 (19.6)</td>
<td></td>
</tr>
<tr>
<td>ILC</td>
<td>3</td>
<td>3 (100.0)</td>
<td>0</td>
<td>(0)</td>
</tr>
<tr>
<td>DCIS-IDC</td>
<td>22</td>
<td>17 (77.3)</td>
<td>5 (22.7)</td>
<td></td>
</tr>
<tr>
<td>Mucinous</td>
<td>2</td>
<td>1 (50.0)</td>
<td>1 (50.0)</td>
<td></td>
</tr>
<tr>
<td><strong>ER Status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>56</td>
<td>43 (76.8)</td>
<td>13 (23.2)</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>17</td>
<td>15 (88.2)</td>
<td>2 (11.8)</td>
<td></td>
</tr>
<tr>
<td><strong>PR status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>47</td>
<td>39 (82.9)</td>
<td>9 (17.1)</td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>26</td>
<td>20 (76.9)</td>
<td>6 (23.1)</td>
<td></td>
</tr>
<tr>
<td><strong>HER-2 Status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>49</td>
<td>40 (81.6)</td>
<td>9 (18.4)</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>24</td>
<td>16 (66.7)</td>
<td>8 (33.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Ki-67</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤14%</td>
<td>16</td>
<td>14 (87.5)</td>
<td>2 (12.5)</td>
<td></td>
</tr>
<tr>
<td>&gt;14%</td>
<td>57</td>
<td>44 (77.2)</td>
<td>13 (22.8)</td>
<td></td>
</tr>
<tr>
<td><strong>CEUS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>19</td>
<td>16 (84.2)</td>
<td>3 (15.8)</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>54</td>
<td>42 (77.8)</td>
<td>12 (22.2)</td>
<td></td>
</tr>
<tr>
<td><strong>SGFR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>49</td>
<td>40 (81.6)</td>
<td>9 (18.4)</td>
<td></td>
</tr>
<tr>
<td>Positive</td>
<td>24</td>
<td>16 (66.7)</td>
<td>8 (33.3)</td>
<td></td>
</tr>
<tr>
<td><strong>Number of LN by US</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>54</td>
<td>42 (77.8)</td>
<td>12 (22.2)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>19</td>
<td>16 (84.2)</td>
<td>3 (15.8)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>2 (100)</td>
<td>0</td>
<td>(0)</td>
</tr>
<tr>
<td><strong>Lymphatic structure</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>71</td>
<td>57 (80.3)</td>
<td>14 (19.7)</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>2</td>
<td>1 (50.0)</td>
<td>1 (50.0)</td>
<td></td>
</tr>
<tr>
<td><strong>S/I aspect ratio of US</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2</td>
<td>23</td>
<td>17 (73.9)</td>
<td>6 (26.1)</td>
<td></td>
</tr>
<tr>
<td>≥2</td>
<td>50</td>
<td>41 (82.0)</td>
<td>9 (18.0)</td>
<td></td>
</tr>
<tr>
<td><strong>Cortical medulla boundary</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clear</td>
<td>54</td>
<td>46 (85.2)</td>
<td>9 (14.8)</td>
<td></td>
</tr>
<tr>
<td>Lack of clarity</td>
<td>19</td>
<td>16 (84.2)</td>
<td>3 (15.8)</td>
<td></td>
</tr>
<tr>
<td><strong>Number of LN by CEUS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>6</td>
<td>2 (33.3)</td>
<td>4 (66.7)</td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>49</td>
<td>41 (83.7)</td>
<td>8 (16.3)</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>16</td>
<td>14 (87.5)</td>
<td>2 (12.5)</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2</td>
<td>1 (50.0)</td>
<td>1 (50.0)</td>
<td></td>
</tr>
<tr>
<td><strong>CEUS-enhanced mode</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>53</td>
<td>47 (89.7)</td>
<td>6 (11.3)</td>
<td></td>
</tr>
<tr>
<td>II/III</td>
<td>20</td>
<td>11 (55.0)</td>
<td>9 (45.0)</td>
<td></td>
</tr>
<tr>
<td><strong>S/I aspect ratio of CEUS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2</td>
<td>36</td>
<td>27 (75.0)</td>
<td>11 (25.0)</td>
<td></td>
</tr>
<tr>
<td>≥2</td>
<td>35</td>
<td>31 (88.6)</td>
<td>4 (11.4)</td>
<td></td>
</tr>
<tr>
<td><strong>S/I aspect ratio of mammography</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;2</td>
<td>48</td>
<td>44 (91.7)</td>
<td>4 (8.3)</td>
<td></td>
</tr>
<tr>
<td>≥2</td>
<td>25</td>
<td>14 (56.0)</td>
<td>11 (44.0)</td>
<td></td>
</tr>
</tbody>
</table>

1. T ≤0.1 cm is T1mi, 0.1 cm < T ≤2 cm is T1, 2 cm < T ≤5 cm is T2, T >5 cm is T3; if; histological grade was missing in 17 participants.
2. BMI, body mass index; ILC, invasive lobular carcinoma; IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; invasive ductal carcinoma; ER, estrogen/progesterone receptor; PR, human epidermal growth factor receptor-2; ER/PR, human epidermal growth factor receptor; CEUS, contrast-enhanced ultrasonography.